Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Declines By 33.9%

Achilles Therapeutics plc (NASDAQ:ACHL) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 90,300 shares, a drop of 33.9% from the November 30th total of 136,700 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 163,100 shares, the short-interest ratio is currently 0.6 days.

Hedge Funds Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC lifted its holdings in Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,100,002 shares of the company’s stock after buying an additional 3,474,828 shares during the quarter. Achilles Therapeutics comprises 2.5% of BML Capital Management LLC’s portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Trading Down 1.7 %

NASDAQ:ACHL opened at $1.13 on Friday. The stock has a market capitalization of $46.44 million, a P/E ratio of -0.68 and a beta of 1.37. Achilles Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.76. The firm has a 50 day moving average of $1.04 and a 200-day moving average of $0.91.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.